Accelerated infliximab induction therapy in inflammatory bowel disease
DOI:
https://doi.org/10.22516/25007440.1546Keywords:
Inflammatory bowel diseases, infliximab, ulcerative colitis, Crohn’s disease, biological therapyAbstract
Introduction: Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), represents a therapeutic challenge, especially in moderate-to-severe cases and in patients with previous anti-TNF failure. Accelerated infliximab induction, using higher doses or shorter intervals than the standard regimen, has been proposed to achieve faster inflammatory control in patients with a high inflammatory burden or refractory disease. However, evidence in Latin American settings remains limited. The objective of this study was to describe the clinical outcomes of patients with IBD treated with accelerated infliximab induction at a Colombian referral center.
Methodology: Observational, descriptive case series that included adult and pediatric patients with UC or CD treated between January 2022 and December 2023 with infliximab 10 mg/kg at weeks 0, 1, and 2. The study evaluated clinical remission, the need for therapeutic escalation, and the requirement for surgery through a review of medical records.
Results: The study included five patients (four men; three adults and two pediatric patients), all with previous anti-TNF exposure. Three had UC and two had CD. Only one pediatric patient with CD achieved clinical remission. Four did not respond, three required a change in medication to tofacitinib or vedolizumab, and two underwent surgery. No serious adverse events were documented.
Conclusion: In this highly refractory cohort, accelerated induction showed a low remission rate and a frequent need for therapeutic escalation.
Downloads
References
Sokić-Milutinović A, Milosavljević T. Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy. Dig Dis. 2024;42(4):325–35. https://doi.org/10.1159/000535647
Cohn HM, Dave M, Loftus EV Jr. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(8):1301–15. https://doi.org/10.1097/MIB.0000000000001199
Dong Y, Xu T, Xiao G, Hu Z, Chen J. Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease. Front Bioeng Biotechnol. 2022;10:909591. https://doi.org/10.3389/fbioe.2022.909591
Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol. 2024;30(15):2068–80. https://doi.org/10.3748/wjg.v30.i15.2068
Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56–61. https://doi.org/10.1016/j.coph.2015.11.003
Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, et al. Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27 Suppl 2:S38–62. https://doi.org/10.1093/ibd/izab190
Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2496–508. https://doi.org/10.1053/j.gastro.2021.04.022
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152
DailyMed. INFLECTRA (infliximab-dyyb) for injection, for intravenous use [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2024 [consultado el 10 de septiembre de 2024]. Disponible en: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. https://doi.org/10.1038/ajg.2009.727
Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, et al. Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-α independent Crohn disease. Med (United States). 2016;95(16):e3417. https://doi.org/10.1016/j.medj.2016.09.002
Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol. 2019;85(4):782–95. https://doi.org/10.1111/bcp.13859
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(11):981-996. https://doi.org/10.1016/S2468-1253(24)00200-0
Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330-335.e1. https://doi.org/10.1016/j.cgh.2014.07.041
Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, et al. Dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45(5):617–30. https://doi.org/10.1111/apt.13913
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. https://doi.org/10.1056/NEJMoa050516
Julião F, Márquez J, Aristizábal N, Yepes C, Zuleta J, Gisbert JP. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a Latin American referral population. Digestion. 2013;88(4):222–8. https://doi.org/10.1159/000355529
Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, et al. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024;9(3):263–72. https://doi.org/10.1016/S2468-1253(23)00421-5
Yamamoto-Furusho JK, Parra-Holguín NN, Julião-Baños F, Puentes F, López R, Bosques-Padilla F, et al. Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean. Med (United States). 2022;101(3):E28624. https://doi.org/10.1097/MD.0000000000028624
World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. https://doi.org/10.1001/jama.2013.281053
Ministerio de Salud. Resolución Número 8430 de 1993, por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud [Internet]. Colombia: MinSalud; 1993 [consultado el 10 de agosto de 2024]. Disponible en: https://www.minsalud.gov.co/sites/rid/lists/bibliotecadigital/ride/de/dij/resolucion-8430-de-1993.pdf
Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64(5):1119–28. https://doi.org/10.1007/s10620-018-5407-7
Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center. Dig Dis Sci. 2020;65(6):1800–5. https://doi.org/10.1007/s10620-019-05957-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 17 |
| Galley views | 6 |
| PDF Views | 6 |
| HTML views | 0 |
| Other views | 0 |














